Nuvectis Pharma (NASDAQ:NVCT) Trading Up 0.5% – Still a Buy?

Nuvectis Pharma, Inc. (NASDAQ:NVCT)’s stock price shot up 0.5% on Friday . The company traded as high as $7.91 and last traded at $7.75. 22,642 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 93,148 shares. The stock had previously closed at $7.71.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Nuvectis Pharma in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating on shares of Nuvectis Pharma in a research report on Wednesday, December 3rd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Nuvectis Pharma presently has an average rating of “Moderate Buy” and an average target price of $15.33.

Nuvectis Pharma Price Performance

The firm has a fifty day simple moving average of $6.59 and a two-hundred day simple moving average of $6.84. The firm has a market cap of $198.48 million, a price-to-earnings ratio of -5.66 and a beta of -0.27.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.20). Equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Insider Activity at Nuvectis Pharma

In related news, CEO Ron Bentsur acquired 5,000 shares of Nuvectis Pharma stock in a transaction on Wednesday, November 5th. The stock was bought at an average cost of $5.72 per share, for a total transaction of $28,600.00. Following the completion of the transaction, the chief executive officer owned 3,525,924 shares of the company’s stock, valued at approximately $20,168,285.28. The trade was a 0.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Marlio Charles Mosseri acquired 72,836 shares of the business’s stock in a transaction on Monday, October 27th. The shares were purchased at an average price of $6.28 per share, with a total value of $457,410.08. Following the completion of the purchase, the insider owned 3,136,576 shares in the company, valued at $19,697,697.28. This represents a 2.38% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 183,770 shares of company stock worth $1,125,193 over the last 90 days. 30.52% of the stock is owned by insiders.

Institutional Trading of Nuvectis Pharma

Several institutional investors have recently made changes to their positions in NVCT. Goldman Sachs Group Inc. purchased a new stake in Nuvectis Pharma in the first quarter valued at $446,000. OMERS ADMINISTRATION Corp purchased a new stake in Nuvectis Pharma during the 1st quarter worth approximately $321,000. Marshall Wace LLP raised its stake in shares of Nuvectis Pharma by 63.6% in the second quarter. Marshall Wace LLP now owns 63,613 shares of the company’s stock valued at $475,000 after acquiring an additional 24,739 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Nuvectis Pharma in the 1st quarter valued at about $413,000. Finally, New York State Common Retirement Fund purchased a new position in Nuvectis Pharma in the second quarter valued at $97,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.